Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
- 1 June 2011
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (6) , 1128-1131
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 TrialJournal of Clinical Oncology, 2012
- Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumorsCancer, 2010
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplificationCancer Science, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005